OBJECTIVE: To determine risk factors associated with drug resistant tuberculosis (TB) in mainland China. METHODS: PubMed and Chinese BioMedical databases were searched. Cohort, case-control and cross-sectional studies providing effect estimates of risk factors for any-drug resistant or multidrug resistant (MDR) TB were included. RESULTS: The meta-analysis included 16 studies. Any-drug resistant TB was significantly associated with poor quality directly observed treatment, shortcourse (DOTS) (odds ratio [OR] 2.65, 95% confidence interval [CI] 1.22, 5.79), long term illness > 1 year (OR 2.71, 95% CI 1.34, 5.48), poor treatment adherence (OR 2.00, 95% CI 1.17, 3.40), previous treatment (OR 4.54, 95% CI 2.71, 7.61) and age 40 -60 years (OR 1.62, 95% CI 1.10, 2.38 ). MDR-TB was significantly associated with poor quality DOTS (OR 1.84, 95% CI 1.36, 2.49) , poor treatment adherence (OR 4.39, 95% CI 2.97, 6.50), previous treatment (OR 3.83, 95% CI 2.12, 6.89) and poverty (OR 1.87, 95% CI 1.38, 2.52). CONCLUSIONS: Previous treatment, poor quality DOTS, poor treatment adherence, long term illness, age 40 -60 years and poverty are associated with a greater risk of drug resistant TB in mainland China.
Introduction
Tuberculosis (TB) remains one of the greatest health problems for people living in the developing world. 1 China has the second highest prevalence of TB worldwide 2 and one of the highest rates of drug resistant TB. 3 Based on a recent national anti-TB drug resistance survey, it was estimated that approximately 120 000 new multidrug resistant (MDR) TB cases emerge annually in China, including 9000 extensively drug resistant TB (XDR-TB) cases, accounting for approximately 24% of the global MDR-TB burden. 4 The emergence of drug resistant TB, especially MDR-TB 5 and XDR-TB, 6, 7 poses a substantial threat to TB control programs worldwide. In addition to the direct transmission of drug resistant strains from one individual to another, 8 9 -18 but there was little consensus between different study populations.
For example, floating populations were strongly associated with drug resistant TB in some studies, 9, 11, 17 but this association was not significant in another study. 10 A nationwide survey on the risk factors associated with drug resistant TB in mainland China has not been performed. The present meta-analysis aimed to weigh the strength and quality of the evidence of a causal association between risk factors and drug resistant TB and MDR-TB in mainland China.
Materials and methods

LITERATURE SEARCH
The PubMed and Chinese BioMedical databases were searched by two researchers (X.J.L., S.F.Z.) to identify relevant publications indexed before October 2011. The following search terms were used as a combination of free text and thesaurus terms: 'tuberculosis'; 'drug resistance'; 'multi-drug resistance'; 'China'; 'risk factors'; and 'epidemiologic determinants'. The Chinese Journal of Tuberculosis and Respiratory Diseases and the Journal of the Chinese Antituberculosis Association were selected as the key journals for hand searching. Each article chosen for inclusion was reviewed for data extraction by three independent reviewers (P.Z., X.S.W., C.Y.L.).
INCLUSION AND EXCLUSION CRITERIA
Original research reports from mainland China published in Chinese and English were included in the review, and comments, editorials and reviews were excluded. Cohort, case-control or cross-sectional studies providing effect estimates of the association between any-drug resistant TB or MDR-TB and risk factors were selected for inclusion. The following types of article were excluded: (i) those with < 10 cases; (ii) those involving drug efficacy testing in vitro or in clinical trials; and (iii) those studying indications for management or the treatment of drug resistant TB. Selected articles were reviewed for information on sample size, population source, age and gender.
STUDY DEFINITIONS
The meta-analysis used the following definitions: MDR-TB, TB resistant to at least both isoniazid and rifampicin; any-drug resistant TB, TB resistant to at least one of four first-line anti-TB drugs (isoniazid, rifampicin, ethambutol and streptomycin) except for MDR-TB cases; poor quality directly observed treatment, short-course (DOTS), not strictly complying with the World Health Organization's (WHO)recommended DOTS strategy; 19 poor treatment adherence, not following the treatment plan, including the increasing or decreasing of drug dosages by patients, antibiotic abuse or short-term interruption of treatment (< 60 days); interruption of treatment, the interruption of treatment for ≥ 60 days in a course of treatment; delay in diagnosis and treatment, > 30 days from the discovery of symptoms to diagnosis.
QUALITY ASSESSMENT
Each article received three independent reviews and was assessed for quality according to the following criteria: (i) cases were defined adequately; (ii) cases were consecutive or obviously representative; (iii) cases and controls were drawn from the same population; (iv) controls were defined adequately; (v) secure record or structured interview blind to case/control status; (vi) same method of diagnosis for cases and controls; (vii) similar nonresponse rate between groups; (viii) study design adequate to measure an association; (ix) adequate definition of risk factors; (x) use of univariate and multivariate analyses. The articles received one point for each of the criteria listed. A score of < 5 was considered to be low quality, 5 -7 was considered medium quality, and > 7 was considered high quality.
STATISTICAL ANALYSES
Data were collected and analysed using Review Manager (RevMan) software, version 4.2 (The Cochrane Collaboration, Oxford, UK). Data heterogeneity was analysed using the χ 2 -test (α = 0.05), with the extent of heterogeneity determined using the I 2 method (I 2 values of 25%, 50% and 75% were indicative of low, medium and high heterogeneity, respectively). Statistically homogenous data were assessed using a fixed effects model. A random effects model was used to interpret heterogeneity further and improve test performance. The fail-safe number for P = 0.05 (N fs0.05 ) was used statistically to assess publication bias (N fs0.05 < 10 was considered indicative of statistically significant publication bias). Sensitivity analysis was performed by two methods (http://www.cochrane-net.org/openlearning/ html/mod14-2.htm): one to exclude those studies that included univariate analyses alone in order to eliminate bias, and the other to exchange analysis models. If the conclusion for some risk factors changed slightly or not at all after using these two methods, the results of the meta-analysis were deemed reliable.
Results
The literature search identified a total of 365 articles published in Chinese or English, 349 of which were excluded from the analysis based on the inclusion and exclusion criteria for the meta-analysis. The final metaanalysis, therefore, included 16 studies from 16 different regions or provinces (the studies being from 16 different regions or provinces was a coincidence). 9 -18,20 -25 All were casecontrol studies published between 2004 and 2010. Of these articles, 11 were extracted from journals, 9,10,12,15,16,20 -25 two were master's degree in medicine (MM) theses, 11, 13 and three were doctoral degree in medicine (MD) dissertations. 14, 17, 18 There were 12 studies regarding risk factors in any-drug resistant TB and 11 in MDR-TB. The quality of the articles was variable, with three of low quality, 21, 23, 24 eight of medium quality, 12 -16,18,22,25 and five of high quality. 9 -11,17,20 Meta-analysis revealed a significant association between any-drug resistant TB and poor quality DOTS (odds ratio [OR] 2.65, 95% confidence interval [CI] 1.22, 5.79), duration of illness > 1 year (OR 2.71, 95% CI 1.34, 5.48), poor treatment adherence (OR 2.00, 95% CI 1.17, 3.40), previous treatment (OR 4.54, 95% CI 2.71, 7.61) and age 40 -60 years (OR 1.62, 95% CI 1.10, 2.38) ( Fig. 1 ).
There was a significant association between MDR-TB and poor quality DOTS (OR 1.84, 95% CI 1.36, 2.49), poor treatment adherence (OR 4.39, 95% CI 2.97, 6.50), previous treatment (OR 3.83, 95% CI 2.12, 6.89), poverty (OR 1.87, 95% CI 1.38, 2.52), floating population (OR 1.44, 95% CI 1.08, 1.91) and smoking (OR 1.37, 95% CI 1.08, 1.76) ( Fig. 2) .
Although MDR-TB was associated with a floating population using the fixed effects model approach for sensitivity analysis, this conclusion was reversed in the random model approach (Fig. 3 ). There were no other differences in the findings between the two sensitivity analyses. There were no Drug resistant TB in China multivariate analyses regarding smoking in the studies included in the meta-analysis, and there was evidence of publication bias in MDR-TB studies on smoking (N fs.0.05 = 2; Table  1 ). N fs.0.05 values for all other risk factors assessed in the meta-analysis were > 10, indicating little publication bias (Table 1 ).
Discussion
Studies have identified several risk factors in drug resistant TB worldwide. 8,26 -29 Differences in the social system and living habits of people in mainland China compared with the rest of the world suggest that the social behaviour risk factors for drug FIGURE 1: Forest plots for meta-analysis outcomes of risk factors for any-drug resistant tuberculosis (TB), showing odds ratios (OR) and 95% confidence intervals (CI). Anydrug resistant TB was defined as TB resistant to at least one of four first-line anti-TB drugs (isoniazid, rifampicin, ethambutol and streptomycin), but not both isoniazid and rifampicin. Plots were generated using combined analysis. (A) Poor-quality directly observed treatment, short-course (DOTS), defined as not strictly complying with the World Health Organization's. 19 17 Wei et al. 10 Yang 14 Zheng 13 17 Wei et al. 10 Yang et al. 20 Zheng 13 17 Li et al. 21 Wei et al. 10 17 Lin et al. 16 Shen et al. 9 Wei et al. 10 Zhu Xu et al. 22 Xu et al. 24 Yang 14 Yang et al. 20 2 17 Lin et al. 16 Shen et al. 9 Xu et al. 22 17 Li et al. 21 Lin et al. 16 Shen et al. 9 Zhu et al. 12 
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Total (95% CI) Sun et al. 25 Wang 18 Xu et al. 24 Yang 14 3 17 Lin et al. 16 Sun et al. 25 A previous history of treatment for TB was the most widely reported risk factor for MDR-TB 8,26 -29 and was the strongest risk factor for both any-drug resistant TB and MDR-TB in the present meta-analysis. Drug resistant Mycobacterium tuberculosis strains arise after repeated cycles of killing (during treatment) and regrowth (after treatment). 30 When patients are medicated repeatedly, the mutant strains become dominant. Resistance to a single drug is followed by the emergence of mutant strains that are resistant to multiple drugs, and the occurrence of MDR-TB. 28 In our opinion, it is likely that inadequate treatment is the main reason for drug resistance in previously treated cases. Delays in disease diagnosis or recognition of drug resistance, inappropriate chemotherapy regimens, inadequate or irregular drug supply, and poor adherence by both patients and clinicians are reported reasons for inadequate treatment. 31, 32 The DOTS strategy for TB control was launched by the WHO in 1995. 19 The strategy is based around short course treatment regimens for a minimum of 6 months, but it also requires political commitment, good management practices, sputum smear microscopy for diagnosis, and the direct observation of doses to ensure adherence. 33 To date, DOTS remains the cornerstone of global efforts at TB control. 34 The present meta-analysis showed that poor quality DOTS was associated with a 2.65-fold increased risk of any-drug resistant TB, and a 1.84-fold 35, 36 reduce the incidence of drug resistance 37 and prevent the acquisition of drug resistance. 36, 38 A study of patients with TB in Beijing between 1978 and 1996 found that DOTS could effectively reduce the prevalence of initial drug resistance when the number of patients in floating populations was low, 39 suggesting that good quality DOTS may prevent the development of drug resistance.
In accordance with the findings of others, 26 the present meta-analysis revealed that any-drug resistant TB and MDR-TB were both associated with poor treatment adherence. Improving the treatment compliance of patients with TB may be an effective way to reduce drug resistant TB and increase the cure rate. The reasons for poor treatment adherence in mainland China may include the side-effects of treatment, the advanced age of the population, low education level, poverty and distractions of a busy working life or education. 17, 40 Poor quality DOTS may be related to this poor treatment adherence.
Patients with long term illness (> 1 year) had a 2.71-fold increased risk of any-drug resistant TB in the present analysis. Some drug resistance mutations are spontaneous, and the frequency of mutation is stable. 30 Over time, these mutations build up and drug resistance may occur. 30 The present analysis found no association between MDR-TB and long term illness; this may have been influenced by bias since many of the papers included in the analysis had not studied the association between MDR-TB and long term illness. This association needs to be studied further. The 1.62-fold increase in risk of anydrug resistant TB in patients aged 40 -60 years may be related to the previously reported poor adherence to treatment by patients in this age group. 40 There was no association between MDR-TB and patients aged 40 -60 years in the present analysis, in spite of the inclusion of one report 9 (covering five relevant articles) 9, 12, 14, 16, 17 to the contrary.
The Chinese Ministry of Health's Fourth National Epidemiological Sampling Survey of TB, conducted in 2000, 41 found that 77.9% of all patients with TB in China had below average per capita income, and 53.1% of interrupted treatment and positive sputum smear cases were attributable to poverty. Studies in other countries have also found a close association between poverty and TB or MDR-TB. 42, 43 Poverty was associated with MDR-TB in the present analysis. This may be due to the increased risk of contracting TB in crowded and poor living conditions, 28, 29 as well as the longer infectious period associated with a shortage of medical and healthcare services. 31 There were several limitations to the present analysis. First, the majority of the included studies (14/16) were published in Chinese, 10 -18,21 -25 and the quality of the reports was not as high as those from English language journals. Some studies did not include all the required information, 12, 13 such as the age and gender of the study population. There was heterogeneity in the pooled estimates of any-drug resistant TB and MDR-TB for some risk factors. These factors may be mutually confounding, and the analysis did not include any cohort studies. Secondly, the possibility of publication bias cannot be completely excluded since positive results are more likely to be published, although no major publication bias was observed. Thirdly, meta-analysis has well-known inherent limitations, including publication and citation bias, misclassification bias, selection and inclusion bias, and the • Received for publication 24 November 2011 • Accepted subject to revision 30 November 2011
• Revised accepted 10 February 2012 Copyright © 2012 Field House Publishing LLP combination of heterogeneous data. 44 Metaanalysis reduces random error but does not necessarily reduce (and may even increase) systematic error.
In spite of these limitations, meta-analysis is an attractive approach for combining the findings from independent studies. In this way, the necessary number of patients may be reached and relatively small effects can be detected or excluded with confidence. Metaanalysis can also contribute to considerations regarding the generalizability of study results.
In conclusion, the present meta-analysis indicated that previous treatment is the strongest determinant of drug resistant TB in mainland China, with poor quality DOTS and poor treatment adherence both significantly associated with any-drug resistant TB and MDR-TB. Long term illness (> 1 year) and being aged 40 -60 years were both significantly associated with increased risk of any-drug resistant TB, and poverty was significantly associated with MDR-TB. These social behaviour risk factors deserve special attention in mainland China, and the screening of patients with these risk factors would assist in both the prevention of drug resistance and the control of TB in general.
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